ClinicalTrials.gov identifier: NCT00775476.
Systemic Lupus Erythematosus
N-acetylcysteine reduces disease activity by blocking mammalian target of rapamycin in T cells from systemic lupus erythematosus patients: A randomized, double-blind, placebo-controlled trial†
Article first published online: 27 AUG 2012
Copyright © 2012 by the American College of Rheumatology
Arthritis & Rheumatism
Volume 64, Issue 9, pages 2937–2946, September 2012
How to Cite
Lai, Z.-W., Hanczko, R., Bonilla, E., Caza, T. N., Clair, B., Bartos, A., Miklossy, G., Jimah, J., Doherty, E., Tily, H., Francis, L., Garcia, R., Dawood, M., Yu, J., Ramos, I., Coman, I., Faraone, S. V., Phillips, P. E. and Perl, A. (2012), N-acetylcysteine reduces disease activity by blocking mammalian target of rapamycin in T cells from systemic lupus erythematosus patients: A randomized, double-blind, placebo-controlled trial. Arthritis & Rheumatism, 64: 2937–2946. doi: 10.1002/art.34502
- Issue published online: 27 AUG 2012
- Article first published online: 27 AUG 2012
- Accepted manuscript online: 1 MAY 2012 11:48AM EST
- Manuscript Accepted: 5 APR 2012
- Manuscript Received: 16 AUG 2011
- NIH. Grant Numbers: AT-004332, AI-072648
- Alliance for Lupus Research
- Central New York Community Foundation
Additional Supporting Information may be found in the online version of this article.
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.